Alterity Therapeutics Limited (ATH.AX)
- GlobeNewswire
Alterity Therapeutics Announces Presentation of Novel Biomarker Data for Evaluation of Multiple System Atrophy
MELBOURNE, Australia and SAN FRANCISCO, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced a poster presentation from the Company’s Biomarkers of progression in Multiple System Atrophy (bioMUSE) Natural History Study at the recent 34th International Symposium on the Autonomic Nervous System (AAS). The poster enti
- Simply Wall St.
Alterity Therapeutics Limited's (ASX:ATH) CEO Compensation Is Looking A Bit Stretched At The Moment
Key Insights Alterity Therapeutics' Annual General Meeting to take place on 28th of November CEO David Stamler's total...
- GlobeNewswire
Alterity Therapeutics Announces Presentation of New Data Demonstrating Novel Mechanisms of ATH434
MELBOURNE, Australia and SAN FRANCISCO, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced promising new data related to ATH434 was presented at the Society for Neuroscience that took place November 11-15, 2023, in Washington, D.C. The poster entitled, “Potent Antioxidant and Mitochondrial-protectant Effects of A
